Swiss Biotechs Gain Momentum with FDA Fast Track Option for Palmoplantar Pustulosis

A trio of Swiss biotechnology companies is advancing diverse therapeutic pipelines, with recent developments spanning inflammatory skin disease, immune‑mediated hair loss, and hard‑to‑treat cancers. Together, these milestones highlight how distinct…

Continue Reading Swiss Biotechs Gain Momentum with FDA Fast Track Option for Palmoplantar Pustulosis